AllianceBernstein Portfolio holdings
AllianceBernstein (AB), formed in 2000 through the merger of Alliance Capital and Bernstein, is a global asset management firm headquartered in Nashville, Tennessee, managing over $759 billion in assets as of late 2024 for institutional investors, financial advisors, and individuals. Known for its research-driven approach, AB offers a diverse range of investment strategies, including equities, fixed income, alternatives, and multi-asset solutions, with a strong emphasis on active management and ESG (environmental, social, governance) integration. The firm, which relocated its headquarters from New York City to Nashville in 2021, operates globally with significant operations in New York, London, and Asia, leveraging its Bernstein Research arm for deep market insights. With a workforce of over 4,700 and a partnership structure led by CEO Seth Bernstein, AB combines a legacy of rigorous analysis with a modern focus on sustainable investing and client outcomes.
Top Buys
| 1 |
Broadcom
AVGO
|
+$683M |
| 2 |
Cboe Global Markets
CBOE
|
+$403M |
| 3 |
Apple
AAPL
|
+$358M |
| 4 |
TSMC
TSM
|
+$352M |
| 5 |
Eli Lilly
LLY
|
+$328M |
Top Sells
| 1 |
Microsoft
MSFT
|
+$1.29B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$636M |
| 3 |
West Pharmaceutical
WST
|
+$562M |
| 4 |
Idexx Laboratories
IDXX
|
+$444M |
| 5 |
Visa
V
|
+$387M |
Sector Composition
| 1 | Technology | 26.49% |
| 2 | Healthcare | 13.1% |
| 3 | Financials | 12.21% |
| 4 | Consumer Discretionary | 11.26% |
| 5 | Communication Services | 9.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3026
Clarus
CLAR
$154M
| $127K | ﹤0.01% |
33,824
| – | – |
|
3027
Capricor Therapeutics
CAPR
$296M
| $126K | ﹤0.01% |
13,280
| – | – |
|
3028
FuelCell Energy
FCEL
$118M
| $126K | ﹤0.01% |
27,454
-16,013
| -37% | -$73.5K |
|
|
TGB
3029
Taseko Mines
TGB
$1.07B
| $124K | ﹤0.01% |
55,460
| – | – |
|
3030
Voyager Therapeutics
VYGR
$222M
| $124K | ﹤0.01% |
36,750
| – | – |
|
3031
Indivior
INDV
$3.08B
| $124K | ﹤0.01% |
13,034
| – | – |
|
|
AOMR
3032
Angel Oak Mortgage REIT
AOMR
$233M
| $124K | ﹤0.01% |
12,980
| – | – |
|
3033
Wolfspeed
WOLF
$285M
| $122K | ﹤0.01% |
39,799
-5,489
| -12% | -$16.8K |
|
|
TUYA
3034
Tuya Inc
TUYA
$1.56B
| $121K | ﹤0.01% |
39,820
| – | – |
|
3035
Zevra Therapeutics
ZVRA
$461M
| $121K | ﹤0.01% |
16,100
| – | – |
|
3036
Bioventus
BVS
$486M
| $121K | ﹤0.01% |
13,170
| – | – |
|
3037
Aquestive Therapeutics
AQST
$602M
| $120K | ﹤0.01% |
41,290
| – | – |
|
|
EIM
3038
Eaton Vance Municipal Bond Fund
EIM
$562M
| $119K | ﹤0.01% |
11,970
| – | – |
|
3039
Lyell Immunopharma
LYEL
$253M
| $119K | ﹤0.01% |
11,040
| – | – |
|
3040
Torrid Holdings
CURV
$188M
| $119K | ﹤0.01% |
21,640
+40
| +0.2% | +$219 |
|
3041
Cadiz
CDZI
$285M
| $118K | ﹤0.01% |
40,290
+8,700
| +28% | +$25.5K |
|
3042
Aehr Test Systems
AEHR
$803M
| $117K | ﹤0.01% |
16,020
| – | – |
|
3043
Ventyx Biosciences
VTYX
$170M
| $117K | ﹤0.01% |
101,330
| – | – |
|
3044
Fate Therapeutics
FATE
$113M
| $116K | ﹤0.01% |
146,580
| – | – |
|
3045
Entrada Therapeutics
TRDA
$196M
| $115K | ﹤0.01% |
12,770
| – | – |
|
3046
Asure Software
ASUR
$222M
| $115K | ﹤0.01% |
12,060
-1,680
| -12% | -$16K |
|
3047
Lands' End
LE
$432M
| $114K | ﹤0.01% |
11,220
-1,280
| -10% | -$13K |
|
3048
Lexicon Pharmaceuticals
LXRX
$411M
| $113K | ﹤0.01% |
246,121
| – | – |
|
3049
GoPro
GPRO
$264M
| $113K | ﹤0.01% |
170,830
| – | – |
|
3050
Virgin Galactic
SPCE
$183M
| $113K | ﹤0.01% |
37,334
| – | – |
|